0798-0000-19-037-H01-P (for Pharmacists) August (1.0 contact hours)

Chemotherapy induced nausea and vomiting (CINV) leads to morbidity and complications in care and occurs in up to 80% of patients. Despite the recent advances in newly available antiemetics, approximately 50% of patients experience CINV which can have a severe effect on the cancer patient’s quality of life. In addition to CINV having a substantial negative impact on the patient’s quality of life, it can also lead to chemotherapy delays, dose reductions, or discontinuation of therapy. CINV can be a major barrier to therapy if not treated appropriately. With the development of therapy options in a wider range of classes, it is possible for more patients to better control their CINV. Antiemetic guidelines should be utilized when choosing CINV prevention therapy, both pharmacologic and non-pharmacologic. Nausea and vomiting prevention should be a combination of lifestyle and medication therapy to achieve the best possible results.